Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma

Original Article

T.K. Choueiri, R.J. Motzer, J.A. Karam, W. Yip, C. Suárez, D. Ye, Z. He, C. Caglevic, T. Ferguson, Y.-H. Chang, C. Rojas, R. Iacovelli, Y. Ürün, E. Verzoni, J.C.V. Limón, C. Porta, R.G. Uzzo, J.L. Lee, B. Venugopal, R.R. McKay, H. Hammers, H. Miyake, J. Chahoud, H. Liu, J.E. Burgents, M. Sharma, and T.B. Powles

N Engl J Med 2026;395:32-43

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Course opens: 
07/01/2026
Course expires: 
07/02/2028

Available Credit

  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Please sign in or create an account to take the course.